Medical condition
Multiple Myeloma
Multiple Myeloma is a medical condition tracked by NovaPharmaNews across 12 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- linvoseltamab (LYNOZYFIC) Antineoplastic and immunomodulating agents (L01)
- plerixafor (PLERIXAFOR ARX) Antineoplastic and immunomodulating agents (L03)
- doxorubicin hydrochloride (CELDOXOME PEGYLATED LIPOSOMAL) Antineoplastic and immunomodulating agents (L01)
- lenalidomide (LENALIDE) Antineoplastic and immunomodulating agents (L04)
- selinexor (XPOVIO) Antineoplastic and immunomodulating agents (L01)
- ixazomib (NINLARO) Antineoplastic and immunomodulating agents (L01)
- bortezomib (BORTEZOM) Antineoplastic and immunomodulating agents (L01)
- pomalidomide (POMALIDOMIDE SANDOZ) Antineoplastic and immunomodulating agents (L04)
- carfilzomib (KYPROLIS) Antineoplastic and immunomodulating agents (L01)
- dexamethasone (DEXMETHSONE) Systemic hormonal preparations (H02)
- epoetin alfa (EPOSTIM) Blood and blood forming organs (B03)
- elranatamab (ELREXFIO)
Latest Multiple Myeloma news
FDA MRD guidance in multiple myeloma: what BD teams should track
The FDA has issued draft guidance on using MRD and complete response as endpoints in multiple myeloma trials. This plan frames what changed, why MRD matters for accelerated approval, and what BD teams and investors should watch next.
Tempest Therapeutics TPST-2003 CAR-T Shows Promise for Multiple Myeloma at ISCT 2026
Tempest Therapeutics presents positive TPST-2003 dual-targeting CAR-T data for relapsed/refractory multiple myeloma patients at ISCT 2026 meeting.
Pfizer's ELREXFIO Shows Significant Progression-Free Survival Improvement in Multiple Myeloma Phase 3 Trial
Pfizer's ELREXFIO meets primary endpoint in MagnetisMM-5 Phase 3 trial, showing statistically significant progression-free survival improvement for relapsed multiple myeloma patients.
FDA Extends Sanofi Sarclisa Subcutaneous Review by Three Months for Multiple Myeloma Treatment
FDA extends Sarclisa subcutaneous review by 3 months. Sanofi's multiple myeloma treatment seeks approval across all current IV indications.
FDA Approves Talvey (talquetamab) for Relapsed Multiple Myeloma
The FDA has granted approval for Talvey (talquetamab), a groundbreaking treatment option for patients with relapsed multiple myeloma, enhancing therapeutic choices.